Skip to content

ORAGENICS, INC.: 10-Q filed 2024-11-13

What ORAGENICS, INC. reported in its quarterly report filed 2024-11-13 (fiscal Q3 2024): 30 published measures, 93 facts as tagged in accession 0001493152-24-045067.

This filing

Form
10-Q (quarterly report)
Filed
2024-11-13
Fiscal period
fiscal Q3 2024
Accession
0001493152-24-045067 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ORAGENICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-09-305,204,093USD
At 2023-12-314,966,335USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2024-09-302,126,506USD
At 2023-12-311,798,181USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-09-303,077,587USD
At 2024-06-301,326,396USD
At 2024-03-312,625,266USD
At 2023-12-313,168,154USD
At 2023-09-306,497,321USD
At 2023-06-307,257,473USD
At 2023-03-3110,244,431USD
At 2022-12-3113,009,302USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-09-303,144,049USD
At 2023-12-313,483,501USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-2,462,870USD92
2024-01-01 to 2024-09-30-7,218,795USD274
2024-04-01 to 2024-06-30-2,305,090USD91
2024-01-01 to 2024-03-31-2,450,833USD91
2023-07-01 to 2023-09-30-2,012,885USD92
2023-01-01 to 2023-09-30-7,908,308USD273
2023-04-01 to 2023-06-30-3,050,586USD91
2023-01-01 to 2023-03-31-2,844,837USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-01-01 to 2024-09-30-6,579,029USD274
2023-01-01 to 2023-09-30-6,188,335USD273

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2023-07-01 to 2023-09-307,466USD92
2023-01-01 to 2023-09-3037,653USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-01-01 to 2024-09-306,239,577USD274
2023-01-01 to 2023-09-30464,479USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-09-3063,715USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-09-30-213,437,047USD
At 2023-12-31-206,218,254USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-07-01 to 2024-09-306,528,064shares92
2024-01-01 to 2024-09-304,857,182shares274
2023-07-01 to 2023-09-302,356,065shares92
2023-01-01 to 2023-09-302,136,340shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-07-01 to 2024-09-306,528,064shares92
2024-01-01 to 2024-09-304,857,182shares274
2023-07-01 to 2023-09-302,356,065shares92
2023-01-01 to 2023-09-302,136,340shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.38USD/shares92
2024-01-01 to 2024-09-30-1.49USD/shares274
2023-07-01 to 2023-09-30-0.85USD/shares92
2023-01-01 to 2023-09-30-3.7USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-0.38USD/shares92
2024-01-01 to 2024-09-30-1.49USD/shares274
2023-07-01 to 2023-09-30-0.85USD/shares92
2023-01-01 to 2023-09-30-3.7USD/shares273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-01-01 to 2024-09-30458,366USD274
2023-01-01 to 2023-09-30546,519USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-2,437,280USD92
2024-01-01 to 2024-09-30-7,203,383USD274
2023-07-01 to 2023-09-30-2,094,446USD92
2023-01-01 to 2023-09-30-8,108,579USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-09-304,113,343USD
At 2023-12-313,865,774USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-07-01 to 2024-09-302,437,280USD92
2024-01-01 to 2024-09-307,203,383USD274
2023-07-01 to 2023-09-302,101,912USD92
2023-01-01 to 2023-09-308,146,232USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-07-01 to 2024-09-30879,041USD92
2024-01-01 to 2024-09-302,449,234USD274
2023-07-01 to 2023-09-30769,350USD92
2023-01-01 to 2023-09-304,448,623USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-09-309,387,547shares
At 2024-09-058,659,071shares
At 2023-12-313,080,693shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-09-30214,912,523USD
At 2023-12-31207,790,604USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-12-319,811USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-09-3065,657USD
At 2023-12-31222,739USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-09-30969,294USD
At 2023-12-31382,273USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-2,462,870USD92
2024-01-01 to 2024-09-30-7,218,795USD274
2023-07-01 to 2023-09-30-2,012,885USD92
2023-01-01 to 2023-09-30-7,908,308USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-07-01 to 2024-09-301,558,239USD92
2024-01-01 to 2024-09-304,754,149USD274
2023-07-01 to 2023-09-301,332,562USD92
2023-01-01 to 2023-09-303,697,609USD273

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-07-01 to 2024-09-309,971USD92
2024-01-01 to 2024-09-3018,859USD274
2023-07-01 to 2023-09-3014,170USD92
2023-01-01 to 2023-09-3018,360USD273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2024-07-01 to 2024-09-30-25,590USD92
2024-01-01 to 2024-09-30-15,412USD274
2023-07-01 to 2023-09-3081,561USD92
2023-01-01 to 2023-09-30200,271USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-01-01 to 2024-09-3018,859USD274
2023-01-01 to 2023-09-303,347USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2024-01-01 to 2024-09-306,669,860USD274
2023-01-01 to 2023-09-30849,808USD273

Inspect the source

Entity
ORAGENICS, INC. / CIK 0001174940
Captured
2026-09-20T07:44:42.616Z
SEC response SHA-256
8765e20cd543bdc7e794aff6d27b475bcedd0539a650dbf34ce59708a51b55de

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001174940.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))